Novo Nordisk may secure more favorable terms under Medicare’s Bridge obesity drug program
Novo Nordisk and Eli Lilly have been profiting from a Medicare pilot that caps obesity drug prices for seniors at $245 a month. Recent analysis suggests Novo could negotiate an even better arrangement under the program.
The potential improvement in pricing could boost Novo's market position as obesity treatments expand. Analysts note that more favorable terms would enhance revenue prospects without altering the drug’s list price.
In related biotech news, Roche reported positive Phase 2 results for its diabetes‑obesity drug enicepatide, while Celldex Therapeutics met Phase 3 goals for a chronic hives therapy and Ionis Pharma advanced an experimental ALS treatment.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Novo may be getting a better deal than expected with Medicare’s Bridge program”
read at STAT ↗
comments(0)
5-min edit window · permanent after that